Asset profile
Obicetrapib
Small molecule
Evidence outlook · lead readout
BROADWAY (NCT05142722) · Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia,...
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
BROADWAY (NCT05142722): Participants were randomized 2:1 to obicetrapib or placebo and the trial was quadruple-blinded, with 2,530 participants enrolled. The primary LDL-cholesterol endpoint was met, with a statistically significant treatment difference, but LDL cholesterol is a surrogate laboratory endpoint rather than a hard clinical or endoscopic measure, supporting a moderate grade.
Also in development:Type 2 Diabetes · Phase 3Homozygous Familial Hypercholesterolemia
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
119 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 117 same-indication; 47 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Obicetrapib: this drug | Phase 3 | Small molecule | CETP | ||
| Dalcetrapib | Phase 3 | Small molecule | CETP | ||
| Dalcetrapib (RO4607381) | Phase 3 | — | CETP | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Bempedoic Acid (Nexletol) | Approved | Small molecule | Adenosine Triphosphate-Citrate Lyase Inhibitor, ATP citrate lyase | ||
| Bempedoic Acid / Ezetimibe | Approved | Small molecule | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe) | ||
| Bexagliflozin (Brenzavvy) | Approved | Small molecule | SGLT2 | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Cangrelor (Kengreal) | Approved | Small molecule | P2Y12 receptor | ||
| Colchicine (cardiovascular) (Lodoco) | Approved | Small molecule | Microtubule/inflammasome (tubulin) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ertugliflozin (Steglatro) | Approved | Small molecule | SGLT2 |
…and 104 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
2027 (1)
November 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.